2025
Effects of Long-Term Cocaine Self-Administration on Kappa Opioid Receptors in Socially Housed Cynomolgus Monkeys as Assessed with PET Imaging and Neuronally Derived Exosomes
Johnson B, Allen M, Nader S, Solingapuram Sai K, Kumar A, Su Y, Singh S, Li S, Huang Y, Deep G, Nader M. Effects of Long-Term Cocaine Self-Administration on Kappa Opioid Receptors in Socially Housed Cynomolgus Monkeys as Assessed with PET Imaging and Neuronally Derived Exosomes. Biological Psychiatry 2025 PMID: 40054763, DOI: 10.1016/j.biopsych.2025.02.900.Peer-Reviewed Original ResearchLong-term cocaine self-administrationKappa-opioid receptorsCocaine Self-AdministrationSelf-AdministrationKappa opioid receptor availabilityPeripheral measuresSocially housed monkeysOpioid receptorsCocaine intakeCocaine SAIntravenous cocaineCocaine misuseBrain regionsCocainePET imagingCynomolgus monkeysSocial rankPET studiesPharmacological interventionsMonkeysPET scansBrainBlood samplesDominant femalesSocial
2024
Problematic Internet Use: A General Perspective
Fineberg N, Grant D, Demetrovics Z, Brand M, Burkauskas J, Corazza O, Gansner M, Gentile D, Gjoneska B, Griffiths M, Király O, Potenza M, Weinstein A. Problematic Internet Use: A General Perspective. 2024, 179-185. DOI: 10.1007/978-3-031-69362-5_25.Peer-Reviewed Original ResearchSystematic Review and Meta-Analysis: Placebo Response in Randomized Controlled Trials of Tourette’s Disorder Medications
Macul Ferreira de Barros P, Farhat L, Behling E, Nasir M, Landeros-Weisenberger A, Bloch M. Systematic Review and Meta-Analysis: Placebo Response in Randomized Controlled Trials of Tourette’s Disorder Medications. Journal Of The American Academy Of Child & Adolescent Psychiatry 2024, 64: 577-592. PMID: 39505141, DOI: 10.1016/j.jaac.2024.10.011.Peer-Reviewed Original ResearchDrug-placebo differencesMagnitude of placebo responseTourette's disorderPlacebo responseStandardized mean changeRandomized Controlled TrialsDrug responsePlacebo-controlled randomized controlled trialsDrug placeboMeta-analysisPsychiatry conditionsClinical-researchDisorder medicationsRandom-effects meta-analysisBetween-groupStandardized mean differencePharmacological interventionsStudy-level characteristicsWithin-groupPlaceboStudy-level factorsMean changeWeb of ScienceControlled TrialsMean differencePharmacological Interventions for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents with Tourette Disorder: A Systematic Review and Network Meta-Analysis
Farhat L, Behling E, Landeros-Weisenberger A, de Barros P, Polanczyk G, Cortese S, Bloch M. Pharmacological Interventions for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents with Tourette Disorder: A Systematic Review and Network Meta-Analysis. Journal Of Child And Adolescent Psychopharmacology 2024, 34: 373-382. PMID: 39320340, PMCID: PMC11807863, DOI: 10.1089/cap.2024.0049.Peer-Reviewed Original ResearchADHD symptomsAttention-deficit/hyperactivity disorderTic severityTourette's disorderAttention-deficit/hyperactivityRandomized Controlled TrialsA2 agonistPharmacological interventionsADHD symptom severityIncreased tic severityPersistent tic disordersNetwork Meta-AnalysisStandardized mean differencePairs of medicationsEfficacy of pharmacological interventionsWorsen ticsRandom-effects network meta-analysisSymptom severityTic disordersADHDMeta-analysisNetwork meta-analysis frameworkCertainty of evidenceDisordersNetwork meta-analysesPharmacological Interventions and an Emerging Understanding of the Need to Consider Sex Differences in Treatment Planning
Fanta A, Bordofsky A, Sebolt C, Jou R. Pharmacological Interventions and an Emerging Understanding of the Need to Consider Sex Differences in Treatment Planning. 2024, 157-167. DOI: 10.1007/978-3-031-62072-0_10.Peer-Reviewed Original ResearchAutism spectrum disorderPharmacological treatmentComorbid disordersCore symptoms of autism spectrum disorderSymptoms of autism spectrum disorderPharmacological treatment of individualsTreating comorbid disordersFDA-approved medicationsTreatment of individualsEffective pharmacological treatmentAnxiety disordersCore symptomsMood disordersEating DisordersASD populationSpectrum disorderSex differencesTreatment of maleDisordersPharmacological interventionsInvestigational clinical trialsNumerous medicationsClinical trialsTreatment planningOCDThe interactions between energy homeostasis and neurovascular plasticity
Chen B, de Launoit E, Meseguer D, Garcia Caceres C, Eichmann A, Renier N, Schneeberger M. The interactions between energy homeostasis and neurovascular plasticity. Nature Reviews Endocrinology 2024, 20: 749-759. PMID: 39054359, DOI: 10.1038/s41574-024-01021-8.Peer-Reviewed Original ResearchWestern dietLifestyle interventionNeurovascular systemCurrent obesity epidemicEnergy homeostasisStable body weightLocal neuronal networksRegulate energy balanceNeuronal networksFood intakeObesity epidemicSedentary lifestylePharmacological interventionsNeurovascular plasticityOverall healthNutritional milieuWeight lossLong-term needsCardiovascular systemBody weightEnergy expenditureAdverse effectsBrain centresLifestyleBrain vasculatureEvolutionary druggability for low-dimensional fitness landscapes toward new metrics for antimicrobial applications
Guerrero R, Dorji T, Harris R, Shoulders M, Ogbunugafor C. Evolutionary druggability for low-dimensional fitness landscapes toward new metrics for antimicrobial applications. ELife 2024, 12: rp88480. PMID: 38833384, PMCID: PMC11149929, DOI: 10.7554/elife.88480.Peer-Reviewed Original ResearchConceptsDrug targetsAllelic variantsStanding genetic variationEmpirical fitness landscapesFitness landscapeGenetic variationB-lactamasePathogenic variantsTarget proteinsVariant sensitivityB-lactamAllelesDrug-target interactionsPathogensMutationsVariantsDrug environmentMechanistic insightDrug developmentMolecular properties of drugsAntimicrobial applicationsApplication metricsLociVariant variablesPharmacological interventionsBehavioral and Psychological Symptoms of Major Neurocognitive Disorders
Tampi R, Tampi D. Behavioral and Psychological Symptoms of Major Neurocognitive Disorders. 2024, 75-89. DOI: 10.1007/978-3-031-55711-8_6.Peer-Reviewed Original ResearchNon-pharmacological interventionsTreatment of BPSDNeuropsychiatric InventoryAssociated with greater caregiver burdenPsychological symptomsNon-pharmacologicalAssessment of BPSDGreater caregiver burdenStandardized assessment toolsSymptoms of BPSDNeurocognitive disordersMajor neurocognitive disorderMental status examinationCaregiver burdenPharmacological interventionsBPSDNoncognitive symptomsAssessment toolDementiaInterventionPharmacological managementPhysical examinationIncreased morbidityComprehensive assessmentSymptomsPharmacological Interventions for Pain Management in Diabetic Peripheral Neuropathy: A Network Meta-analysis of Randomised Controlled Trials (P5-13.003)
Suresh V, Dey D, Jayan M, Shamim M, Gupta S, Ramana D, Dave T, Jena R, Muneer M, Dhakal B, Ghosh S, Verma A, Garg A, Muzammil M, Bardhan M, Malhotra H, Kumar N, Mallick H, Roy B. Pharmacological Interventions for Pain Management in Diabetic Peripheral Neuropathy: A Network Meta-analysis of Randomised Controlled Trials (P5-13.003). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000206325.Peer-Reviewed Original ResearchThe role of epigenetic mechanisms in the long‐term effects of early‐life adversity and mother–infant relationship on physiology and behavior of offspring in laboratory rats and mice
Burenkova O, Grigorenko E. The role of epigenetic mechanisms in the long‐term effects of early‐life adversity and mother–infant relationship on physiology and behavior of offspring in laboratory rats and mice. Developmental Psychobiology 2024, 66: e22479. PMID: 38470450, PMCID: PMC10959231, DOI: 10.1002/dev.22479.Peer-Reviewed Original ResearchConceptsEarly-life adversityEffects of early-life adversityBehavior of offspringMother-infant relationshipRegulation of hypothalamic-pituitary-adrenal axisHypothalamic-pituitary-adrenal axisBrain-derived neurotrophic factorLaboratory ratsMaternity careBehavioral profileEpigenetic mechanismsNeurotrophic factorExperimental manipulationEarly postnatal periodPharmacological interventionsLong-term effectsAdversityLong-term influenceRatsAdaptation of offspringOffspringEpigenetic editingTranslational potentialNatural variationMicePharmacological management of gambling disorder: an update of the literature
Mestre-Bach G, Potenza M. Pharmacological management of gambling disorder: an update of the literature. Expert Review Of Neurotherapeutics 2024, 24: 391-407. PMID: 38357896, DOI: 10.1080/14737175.2024.2316833.Peer-Reviewed Original ResearchGambling disorderCo-occurring disordersSerotonin reuptake inhibitorsPlacebo response ratesOpioid receptor antagonistMental health conditionsGlutamatergic agentsNeurobiological correlatesGambling subtypesMood stabilizersReuptake inhibitorsClasses of medicationsPharmacological treatmentBetting behaviorGamblingTreatment responsePharmacological interventionsDisordersPharmacological managementMedicationTreatment optionsNarrative reviewLongitudinal informationResponse rateNalmefeneNeurovascular effects of cocaine: relevance to addiction
Clare K, Park K, Pan Y, Lejuez C, Volkow N, Du C. Neurovascular effects of cocaine: relevance to addiction. Frontiers In Pharmacology 2024, 15: 1357422. PMID: 38455961, PMCID: PMC10917943, DOI: 10.3389/fphar.2024.1357422.Peer-Reviewed Original ResearchBrain functionAssociated with adverse medical consequencesCerebral blood flowRelevant to addictionHealthy non-drugBrain imaging studiesCerebral blood flow deficitsCocaine addictionAddictive drugsCocaine misuseCocaine useTargeted pharmacological interventionsCocaineNon-drugAdverse medical consequencesNeuronal activityDebilitating neurological complicationsPharmacological interventionsAddictionCBF changesBrainImaging studiesMedical consequencesNeurological complicationsCerebrovascular accidentIntensive care unit interventions to promote sleep and circadian biology in reducing incident delirium: a scoping review
Wilcox M, Burry L, Englesakis M, Coman B, Daou M, van Haren F, Ely E, Bosma K, Knauert M. Intensive care unit interventions to promote sleep and circadian biology in reducing incident delirium: a scoping review. Thorax 2024, 79: 988-997. PMID: 38350730, DOI: 10.1136/thorax-2023-220036.Peer-Reviewed Original ResearchSeverity of deliriumIntensive care unitIncident deliriumCare bundleReducing incident deliriumSensitive search of electronic databasesSearch of electronic databasesEnglish-language studiesPromote sleepPromotion interventionsEvaluate interventionsIntensive care unit interventionsElectronic databasesNon-pharmacologicalInclusion criteriaIntervention strategiesDeliriumInterventionCare unitEye maskConference proceedingsVariable reportingSleepPharmacological interventionsAssociationNeural circuits for the adaptive regulation of fear and extinction memory
Plas S, Tuna T, Bayer H, Juliano V, Sweck S, Perez A, Hassell J, Maren S. Neural circuits for the adaptive regulation of fear and extinction memory. Frontiers In Behavioral Neuroscience 2024, 18: 1352797. PMID: 38370858, PMCID: PMC10869525, DOI: 10.3389/fnbeh.2024.1352797.Peer-Reviewed Original ResearchRegulation of fearExtinction learningExtinction memoryFear memoryNeural mechanismsExtinction of Pavlovian fear conditioningRegulation of fear memoryNeural circuitsPrefrontal-hippocampal interactionsMedial prefrontal cortexExposure-based therapyPavlovian Fear ConditioningThalamic nucleus reuniensStress-related disordersEffects of stressPrefrontal cortexFear conditioningContextual controlNucleus reuniensAdaptive behaviorAdaptive regulationClinical implicationsMemoryRodent modelsPharmacological interventionsPharmacological and non-pharmacological interventions for irritability in autism spectrum disorder: a systematic review and meta-analysis with the GRADE assessment
Choi H, Kim J, Yang H, Kim J, Cortese S, Smith L, Koyanagi A, Dragioti E, Radua J, Fusar-Poli P, Shin J, Cheon K, Solmi M. Pharmacological and non-pharmacological interventions for irritability in autism spectrum disorder: a systematic review and meta-analysis with the GRADE assessment. Molecular Autism 2024, 15: 7. PMID: 38263251, PMCID: PMC10807060, DOI: 10.1186/s13229-024-00585-6.Peer-Reviewed Original ResearchConceptsAutism spectrum disorderNon-pharmacological interventionsRisperidone monotherapyParent trainingPharmacological monotherapySpectrum disorderTreatment of irritabilityRandomized Controlled TrialsAdjuvant therapyRisperidoneReplicate findingsEfficacy of interventionsEffect sizePooled effect sizeHedges’ g.AripiprazoleEligible interventionsMeta-analysisPharmacological interventionsAutismRandom-effects meta-analysisCertainty of evidenceRisk of biasDisordersMeta-analysesAutism Spectrum Disorder (ASD)
Rutten M, Zhong J, Rolison M, Sukhodolsky D. Autism Spectrum Disorder (ASD). 2024, 734-743. DOI: 10.1016/b978-0-323-95702-1.00076-2.ChaptersAutism spectrum disorderSeverity of core symptomsIdentity-first languagePerson-first languageCore symptomsPsychiatric disordersRestricted interestsIntellectual disabilityRepetitive behaviorsSpectrum disorderSensory sensitivityNeurodevelopmental disordersSocial communicationAutismEnvironmental risk factorsAutism communityPharmacological interventionsDisordersAdvanced parental ageParental ageADHDAnxietyLanguagePhenotypic presentationDisability
2023
Mifepristone as a pharmacological intervention for stress‐induced alcohol craving: A human laboratory study
Haass‐Koffler C, Magill M, Cannella N, Brown J, Aoun E, Cioe P, Sinha R, Swift R, Ciccocioppo R, Leggio L. Mifepristone as a pharmacological intervention for stress‐induced alcohol craving: A human laboratory study. Addiction Biology 2023, 28: e13288. PMID: 37369125, PMCID: PMC10313137, DOI: 10.1111/adb.13288.Peer-Reviewed Original ResearchConceptsAlcohol use disorderHuman laboratory studiesAdverse eventsAlcohol pharmacokineticsAlcohol cravingSubjective effectsSafety of mifepristonePlacebo-controlled trialStress-induced alcoholLack of effectCue-reactivity procedureBlood pressurePhase 1/2Alcohol drinkingGeneralized Estimating EquationsYohimbine administrationHemodynamic parametersPharmacological interventionsSaliva outputDay administrationUse disordersMifepristoneNon-treatment seekersAlcohol consumptionPlacebo conditionPharmacological Interventions for Impulsivity in Addictive Disorders
Schwartz E, Palmisano A, Sofuoglu M. Pharmacological Interventions for Impulsivity in Addictive Disorders. Current Addiction Reports 2023, 10: 149-165. DOI: 10.1007/s40429-023-00486-3.Peer-Reviewed Original ResearchAddictive disordersPharmacological interventionsAddiction-related outcomesRecent FindingsSeveral studiesGlutamatergic medicationsGlutamatergic systemPatient populationPharmacological treatmentTreatment approachesMedicationsDisorder outcomesDisordersFurther studiesOutcomesInterventionImpulsivityAddictive behaviorsFacets of impulsivityMore standardizationTrait impulsivityPositive signalsDopaminergicBrazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment
de Oliveira M, de Barros P, de Mathis M, Boavista R, Chacon P, Echevarria M, Ferrão Y, de Queiroz Vattimo E, Lopes A, Torres A, Diniz J, Fontenelle L, do Rosário M, Shavitt R, Miguel E, da Silva R, da Conceição Costa D. Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment. Brazilian Journal Of Psychiatry 2023, 45: 146-161. PMID: 36749887, PMCID: PMC10154009, DOI: 10.47626/1516-4446-2022-2891.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsAdult obsessive-compulsive disorderObsessive-compulsive disorderPharmacological treatmentReuptake inhibitorsEvidence-based pharmacological interventionsFirst-line pharmacological treatmentAmerican Psychiatric Association guidelinesEvidence-based pharmacological treatmentFirst-line treatmentNorepinephrine reuptake inhibitorsPrimary outcome measureSerotonin reuptake inhibitorsGlutamate-modulating agentsHigh-quality evidenceAmerican Heart AssociationLevel of evidenceTreatment of OCDBrazilian Research ConsortiumAdult patientsHeart AssociationTolerable dosesAssociation guidelinesTreatment recommendationsPharmacological interventions
2022
Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis
Farhat L, Behling E, Landeros-Weisenberger A, Levine J, Macul Ferreira de Barros P, Wang Z, Bloch M. Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis. The Lancet Child & Adolescent Health 2022, 7: 112-126. PMID: 36528030, DOI: 10.1016/s2352-4642(22)00316-9.Peer-Reviewed Original ResearchConceptsAntipsychotic drugsTourette syndromeComorbid attention-deficit hyperactivity disorderSecond-generation antipsychotic drugsModerate certainty of evidenceAttention-deficit hyperactivity disorderCertainty of evidenceNetwork Meta-AnalysisPharmacological interventionsSeverity of tic symptomsObsessive-compulsive disorderIndividual medicationsRandomised controlled trialsFirst-generationDiscontinuation due to adverse eventsSecond-generationAntipsychotic medicationControlled TrialsModerate certaintyHyperactivity disorderMeta-analysisTic symptomsChoice of medicationMedication categoriesTourette
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply